Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib maintenance in advanced urothelial cancer
NCT03945084Phase 2Completed
- Sponsor
- University of Turin
- Start
- Aug 2019
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of niraparib in urothelial carcinoma (UC), sponsored by University of Turin. Primary endpoint: Progression-Free Survival at 3 years. Started Aug 2019; status: completed.
02
Drugs
niraparib
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT03945084.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03945084.